RCKT vs SRPT
RCKT: Rocket Pharmaceuticals is a clinical-stage biotechnology company developing transformative gene therapies for rare, high-unmet-need genetic disorders. SRPT: A biopharmaceutical leader in genetic medicine, specializing in innovative RNA-targeted therapies and gene treatments for Duchenne muscular dystrophy and rare genetic disorders.
Side-by-side fundamentals
| Metric | RCKT | SRPT | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $3.61 | $16.78 | |
| Market cap as of 2026-08-09 | $394M | $1.8B | |
| PEG as of 2026-08-09 | n/a | -21.22 | |
| Net margin as of 2026-08-09 | n/a | -6.9% | |
| Gross margin as of 2026-08-09 | n/a | +67.5% | |
| Operating margin as of 2026-08-09 | n/a | -6.4% | |
| ROE as of 2026-08-09 | -70.8% | -10.0% | SRPT higher |
| ROA as of 2026-08-09 | -59.6% | -4.1% | SRPT higher |
| Debt / equity as of 2026-08-09 | 0.09 | 0.55 | RCKT lower |
| Revenue growth (YoY) as of 2026-08-09 | n/a | -20.4% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +33.1% | |
| Beta as of 2026-08-09 | 0.46 | 0.33 | |
| 1-year return as of 2026-08-07 close | +16.8% | -6.6% | RCKT higher |
Fundamentals: market data, as of 2026-08-09. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.